৳ 0.00
Your Complete HealthCare Solution - Right Here
10657
info@shukhee.com
Telecom Bhaban (Level- 12), 53/1 Box Nagar, Zoo Road, Dhaka-1216.
৳ 0.00
10657
info@shukhee.com
Telecom Bhaban (Level- 12), 53/1 Box Nagar, Zoo Road, Dhaka-1216.


Quantity:
Products
Payment
Delivery
Indications: Lipoter tablet is indicated for the treatment of diabetic dyslipidemia and hypertriglyceridemia in patients with Type 2 diabetes mellitus not adequately controlled by statin therapy. Clinical studies have shown that Lipoter reduces triglycerides (TG), low‑density lipoprotein (LDL) cholesterol, very‑low‑density lipoprotein (VLDL) cholesterol, non‑HDL cholesterol, and increases HDL cholesterol. It also improves glycemic control by lowering fasting plasma glucose and glycated hemoglobin (HbA1c) in diabetic patients.
Pharmacology: Saroglitazar is a potent and predominantly PPAR‑α agonist with moderate PPAR‑γ agonistic activity. PPARs are nuclear lipid‑activated transcription factors that regulate genes involved in lipid and lipoprotein metabolism, glucose homeostasis, and inflammation. Activation of PPAR‑α by Saroglitazar increases hepatic oxidation of fatty acids and reduces triglyceride synthesis and secretion. It enhances lipolysis and clearance of TG‑rich particles by activating lipoprotein lipase (LPL) and reducing apolipoprotein C‑III production. Consequently, it lowers plasma TG and LDL cholesterol while increasing HDL cholesterol. PPAR‑γ activation improves insulin sensitivity by regulating genes involved in glucose transport and utilization, such as adiponectin, LPL, and fatty acid transport proteins. This dual action provides both antidyslipidemic and antidiabetic effects.
Dosage & Administration: The recommended dose is 2 mg once daily.
Pediatric use (<10 years): Safety and efficacy not established.
Geriatric use: Use with caution considering comorbidities and concomitant medications.
Interactions: In vitro studies show Saroglitazar does not significantly inhibit or induce major CYP enzymes (CYP1A2, 2C9, 2C19, 2D6, 3A4). Therefore, clinically significant drug interactions are unlikely.
Contraindications: Hypersensitivity to Saroglitazar or any excipients in the formulation.
Side Effects: In clinical trials (12–24 weeks), common adverse events (>2%) included gastritis, asthenia, and pyrexia. Most were mild to moderate and did not require discontinuation.
Pregnancy & Lactation:
Pregnancy Category C: Safety not established; use only if potential benefit justifies potential risk.
Lactation: Unknown if excreted in breast milk; avoid use during breastfeeding.
Precautions & Warnings: Use with caution in patients with abnormal liver or renal function or history of myopathy. Monitor for signs of fluid retention or congestive heart failure, especially in diabetic patients with cardiac disease. Rapid weight gain should prompt evaluation for edema or heart failure.
Overdose Effects: No overdose cases reported. In case of overdose, provide supportive care and monitor vital signs.






Saroglitazar is an oral medication used primarily for the treatment of diabetic dyslipidemia and hypertriglyceridemia. It works as a dual PPAR (peroxisome proliferator-activated receptor) alpha and gamma agonist, helping regulate lipid and glucose metabolism.
Saroglitazar helps reduce triglycerides, improve HDL (good cholesterol), and control blood sugar levels. It is especially useful in patients with type 2 diabetes who have abnormal lipid profiles.
